CYP2C19 and cancer: We demonstrated, both in vitro and in vivo, that FABP4 and FABP5, and their associated CYP2C19/EET signaling axis provide a regulatory mechanism in TNBC metastatic progression, regardless of whether they are intrinsically expressed by cancer cells or are activated through interaction with other cell types.